Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
UPDATE 1-Roche signs global licensing pact for Simcere's experimental blood cancer drug Adding details of the deal in bullets and statement from Simcere spokesperson
Sept 1 (Reuters) - Switzerland's Roche ROPC.S will pay $75 million upfront to Simcere Pharmaceutical Group 2096.HK for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
SIM0660 targets B-cell malignancies, Simcere said in a filing to the Hong Kong stock exchange.
B cells are a type of white blood cell that produces antibodies.
Simcere is also eligible to receive up to about $1.46 billion in payments for unspecified milestones.
Roche will receive exclusive global rights to develop, manufacture and commercialise SIM0660.
A Simcere spokesperson told Reuters SIM0660 is a preclinical product.
Roche did not immediately respond to a request for comment on what specific diseases it intended to study SIM0660 for, or potential clinical trial timelines.
(Reporting by Andrew Silver in Shanghai, additional reporting from Jasmeen Ara Shaikh in Bengaluru; Editing by Anil D'Silva and Louise Heavens)
((andrew.silver@thomsonreuters.com))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660